# A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)

> **NCT04234607** · PHASE3 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 738 (estimated)

## Conditions studied

- Extensive Small Cell Lung Cancer

## Interventions

- **DRUG:** TQB2450
- **DRUG:** Anlotinib
- **DRUG:** Etoposide
- **DRUG:** Carboplatin
- **DRUG:** TQB2450（blank）
- **DRUG:** Anlotinib（blank)

## Key facts

- **NCT ID:** NCT04234607
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01
- **Primary completion:** 2022-12
- **Final completion:** 2022-12
- **Target enrollment:** 738 (ESTIMATED)
- **Last updated:** 2020-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04234607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04234607, "A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04234607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*